2-aminophenoxazine-3-one prevents pulmonary metastasis of mouse B16 melanoma cells in mice

Journal of Pharmacological Sciences

Volumn 114, Issue 1, 2010, Pages 63-68

  Hongo, Takayuki ^a   Miyano Kurosaki, Naoko ^a   Kurosaki, Kunihiko ^b   Hata, Akihiro ^a   Harigae, Satoko ^a   Tomoda, Akio ^c  

^a CHIBA INSTITUTE OF TECHNOLOGY   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

2 aminophenoxazine 3 one; Mouse B16 melanoma cell; Pulmonary metastasis

Indexed keywords

2 AMINOPHENOXAZINE 3 ONE; ANTIMETASTATIC AGENT; DNA; FAS ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS CELL; LUNG METASTASIS; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

EID: 77957931141     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10023FP     Document Type: Article

References (33)

1. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent rends incutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678-683.
2. Pawlik TM, Sodak VK. Malignant melanoma: current state of primary and adjuvant treatment. Oncol Hematol. 2003;45:245-264.
3. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:33-39.
4. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
5. Noltenius C, Noltenius H. Dormant tumor cells in liver and brain. An autopsy study on metastasizing tumors. Pathol Res Pract. 1985;179:504-511.
6. Shimizu S, Suzuki M, Tomoda, A, Arai S, Taguchi H, Hanawa T, et al. Phenoxazine compounds produced by the reactions with bovine hemoglobin show antimicrobial activity against non-tuberculosis mycobacteria. Tohoku J Exp Med. 2004;203:47-52.
7. Anzai K, Isono K, Okuma K, Suzuki S. The new antibiotics, questiomycins A and B. J Antibiot (Tokyo). 1960;13:125-132.
8. Shimizu S, Suzuki M, Miyazawa K, Yokoyama T, Ohyashiki K, Miyazaki K, et al. Differentiation and apoptosis in human malignant melanoma G-361 cells induced by 2-aminophenoxazine-3- one. Oncol Rep. 2005;14:41-46.
9. Miyano-Kurosaki N, Kurosaki K, Hayashi M, Takaku H, Hayafune M, Shirato K, et al. 2-Aminophenoxazine-3-one suppresses the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice. Biol Pharm Bull. 2006;29:2197-2201.
10. Shirato K, Imaizumi K, Abe A, Tomoda A. Phenoxazine derivatives induce caspase-independent cell death in human glioblastoma cell lines, A-172 and U-251. Oncol Rep. 2007;17:201-208.
11. Kasuga T, Tabuchi T, Shirato K, Imaizumi K, Tomoda A. Caspase- independent cell death revealed in human gastric cancer cell lines, MKN45 and KATO III treated with phenoxazine derivatives. Oncol Rep. 2007;17:409-415.
12. Shirato K, Imaizumi K, Miyazawa K, Takasaki A, Mizuguchi J, Che X-F, et al. Apoptosis induction preceded by mitochondrial depolarization in multiple myeloma cell line U266 by 2-aminophenoxazine- 3-one. Biol Pharm Bull. 2008;31:62-67.
13. Che X-F, Akiyama S, Tomoda A. Suppression of the proliferation of cancer cell lines, KB-3-1 and K562 cells preceded by a decrease in intracellular pH caused by phenoxazine derivatives. Oncol Rep. 2008;19:1253-1258.
14. Takasaki A, Hanyu H, Iwamoto T, Shirato K, Izumi R, Toyota H, et al. Mitochondrial depolarization and apoptosis associated with sustained activation of c-jun-N-terminal kinase in the human multiple myeloma cell line U266 induced by 2-aminophenoxazine- 3-one. Mol Med Rep. 2009;2:1199-1203.
15. Miyano-Kurosaki N, Ikegami K, Kurosaki K, Endo T, Aoyagi H, Hanami M, et al. Anticancer effects of phenoxazine derivatives revealed by inhibition of cell growth and viability, disregulation of cell cycle, and apoptosis induction in HTLV-1-positive leukemia cells. J Pharmacol Sci. 2009;110:87-97.
16. Kohno K, Miyake M, Sano O, Tanaka-Kataoka M, Yamamoto S, Koya-Miyata S, et al. Anti-inflammatory and immunomodulatory properties of 2-amino-3H-phenoxazine-3-one. Biol Pharm Bull. 2008;31:1938-1945.
17. Lahdenranta J, Hagendoorn J, Padera TP, Hosihda T, Nelson G, Kashiwagi S, et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res. 2009;69,2801-2815.
18. Neil J, Johson KM, Nemenoff RA, Schiemann WP. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-β through a PGE2-dependent mechanisms. Carcinogenesis. 2008;29:2227-2235.
19. Kamei D, Murakami M, Sasaki Y, Nakatani Y, Ishikawa MY, Ishii T, et al. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumor growth, invasion and metastasis. Biochem J. 2009;425:361-371.
20. Kumar MRS, Aithal K, Rao BN, Udupa N, Rao BSS. Cytotoxic, genotoxic and oxidative stress induced by 1,4-naphthoquinone in B16F1 melanoma tumor cells. Toxicol in Vitro. 2009;23:242-250.
21. Dhein J, Walczaqk H, Baumler C, Debatin KM, Krammer PH. Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature. 1995;373:438-441.
22. Lee S-J, Chung I-M, Kim M-Y, Park K-D, Park W-H, Moon H-I. Inhibition of lung metastasis in mice by oligonol. Phytother Res. 2009;23:1043-1046.
23. Salinas-Jazmin N, de la Fuente M, Jaimez R, Perez-Tapia M, Perez-Torres A, Valasco-Velazquez MA. Antimetastatic, antineoplastic, and toxic effects of 4-hydroxycoumarin in a preclinical mouse melanoma model. Cancer Chemother Pharmacol. 2010;65:931-940.
24. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Tompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell. 1997;91:627-637.
25. Hail N Jr, Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis. 2006;11:889-904.
26. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
27. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
28. Friesen C, Fulda S, Debatin K-M. Deficient activation of the CD95(APO-1/Fas) system in drug-resistant cells. Leukemia. 1997;11:1833-1841.
29. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574-577.
30. Muller M, Strand S, Hug H, Heinemann EM, Watczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99:403-413.
31. Guo H, Shenoy N, Gershman BM, Yang J, Skalar LA, Miao Y. Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide. Nuc Med Biol. 2009;36:267-276.
32. Runkle GP, Znik AJ. Malignant melanoma. Am Fam Physician. 1994;49:91-98.
33. Eckert KG, Eyer P. Defferences in the reactions of isomeric ortho- and para-aminophenols with hemoglobin. Biochem Pharmacol. 1983;32,1019-1027.